A Phase III, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Copanlisib in Combination With Rituximab in Patients With Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) - CHRONOS-3
Phase of Trial: Phase III
Latest Information Update: 20 Oct 2017
At a glance
- Drugs Copanlisib (Primary) ; Rituximab
- Indications Follicular lymphoma; MALT lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Registrational; Therapeutic Use
- Acronyms CHRONOS-3
- Sponsors Bayer
- 09 Oct 2017 Planned number of patients changed from 514 to 567.
- 09 Oct 2017 Planned End Date changed from 1 Dec 2020 to 28 Aug 2020.
- 09 Oct 2017 Planned primary completion date changed from 1 Jun 2020 to 31 Mar 2020.